The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype

Nature Communications

Volumn 7, Issue , 2016, Pages

  Martone, J ^a   Briganti, F ^a   Legnini, I ^a   Morlando, M ^a   Picillo, E ^b   Sthandier, O ^a   Politano, L ^b   Bozzoni, I ^a,c,d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CELF2A PROTEIN; DEFLAZACORT; DYSTROPHIN; FOSINOPRIL; ISOPROTEIN; UNCLASSIFIED DRUG; CELF PROTEIN; CELF2 PROTEIN, HUMAN; NERVE PROTEIN;

DISEASE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC DIFFERENTIATION; GENOTYPE; MUTATION;

ADULT; ARTICLE; BECKER MUSCULAR DYSTROPHY; BREAST MILK; BRONCHOSPASM; CASE REPORT; CHILD HOSPITALIZATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; ELECTROCARDIOGRAM; EXON SKIPPING; GENE DELETION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; MALE; MUSCLE BIOPSY; MYOBLAST; NEWBORN JAUNDICE; PHENOTYPE; PHOTOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT; ADOLESCENT; EXON; GENETICS; METABOLISM; RNA SPLICING;

ADOLESCENT; CELF PROTEINS; DYSTROPHIN; EXONS; GENOTYPE; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; NERVE TISSUE PROTEINS; PHENOTYPE; RNA SPLICING;

EID: 84955475566     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10488     Document Type: Article

References (40)

1. Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H. & Kunkel, L. M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90-95 (1988).
2. Ervasti, J. M. & Sonnemann, K. J. Biology of the striated muscle dystrophin-glycoprotein complex. Int. Rev. Cytol. 265, 191-225 (2008).
3. Minetti, G. C. et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12, 1147-1150 (2006).
4. Colussi, C. et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl Acad. Sci. USA 105, 19183-19187 (2008).
5. Cacchiarelli, D. et al. Micro RNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell. Metab. 12, 341-351 (2010).
6. Bladen, C. L. et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395-402 (2015).
7. Harper, S. Q. et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261 (2002).
8. Anthony, K. et al. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134, 3547-3559 (2011).
9. Sironi, M. et al. Trans-acting factors may cause dystrophin splicing misregulation in BMD skeletal muscles. FEBS Lett. 537, 30-34 (2003).
10. Miyagoe-Suzuki, Y. & Takeda, S. Gene therapy for muscle disease. Exp. Cell Res. 316, 3087-3092 (2010).
11. Goyenvalle, A., Seto, J. T., Davies, K. E. & Chamberlain, J. Therapeutic approaches to muscular dystrophy. Hum. Mol. Genet. 20, R69-R78 (2011).
12. Foster, H., Popplewell, L. & Dickson, G. Genetic therapeutic approaches for Duchenne muscular dystrophy. Hum. Gene. Ther. 23, 676-687 (2012).
13. Douglas, A. G. L. & Wood, M. J. A. Splicing therapy for neuromuscular disease. Mol. Cell. Neurosci. 56, 169-185 (2013).
14. Koo, T. & Wood, M. J. Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. Hum. Gene. Ther. 24, 479-488 (2013).
15. Arechavala-Gomeza, V., Khoo, B. & Aartsma-Rus, A. Splicing modulation therapy in the treatment of genetic diseases. Appl. Clin. Genet. 7, 245-252 (2014).
16. Delaporte, C., Dehaupas, M. & Fardeau, M. Comparison between the growth pattern of cell cultures from normal and Duchenne dystrophy muscle. J. Neurol. Sci. 64, 149-160 (1984).
17. Buckingham, M. & Rigby, P. W. J. Gene regulatory networks and transcriptional mechanisms that control myogenesis. Dev. Cell 28, 225-238 (2014).
18. Twayana, S. et al. Biogenesis and function of non-coding RNAs in muscle differentiation and in Duchenne muscular dystrophy. Biochem. Soc. Trans. 41, 844-849 (2013).
19. Cacchiarelli, D. et al. miR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapy. EMBO Rep. 12, 136-141 (2011).
20. Denti, M. A. et al. Long-term benefit of adeno-associated virus/antisensemediated exon skipping in Dystrophic mice. Hum. Gene Ther. 19, 601-608 (2008).
21. Cazzella, V. et al. Exon 45 skipping through U1-snRNA antisense molecules recovers the Dys-nNOS pathway and muscle differentiation in human DMD myoblasts. Mol. Ther. 20, 2134-2142 (2012).
22. Aartsma-Rus, A. et al. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul. Disord. 12, S71-S77 (2002).
23. Cartegni, L., Wang, J., Zhu, Z., Zhang, M. Q. & Krainer, A. R. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31, 3568-3571 (2003).
24. Gromak, N., Matlin, A. J., Cooper, T. A. & Smith, C. W. Antagonistic regulation of alpha-actinin alternative splicing by CELF proteins and polypyrimidine tract binding protein. RNA 9, 443-456 (2003).
25. Leroy, O. et al. ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J. Neurosci. Res. 84, 852-859 (2006).
26. Charlet, B. N., Logan, P., Singh, G. & Cooper, T. A. Dynamic antagonism between ETR-3 and PTB regulates cell type-specific alternative splicing. Mol. Cell. 9, 649-658 (2002).
27. Anant, S. et al. Novel role for RNA-binding protein CUGBP2 in mammalian RNA editing. CUGBP2 modulates C to U editing of apolipoprotein B mRNA by interacting with apobec-1 and ACF, the apobec-1 complementation factor. J. Biol. Chem. 276, 47338-47351 (2001).
28. Li, D., Bachinski, L. L. & Roberts, R. Genomic organization and isoformspecific tissue expression of human NAPOR (CUGBP2) as a candidate gene for familial arhythmogenic right ventricular dysplasia. Genomics 74, 396-401 (2001).
29. Ladd, A. N., Charlet, N. & Cooper, T. A. The CELF family of RNA binding proteins is implicated in cell-specific and developmentally regulated alternative splicing. Mol. Cell. Biol. 21, 1285-1296 (2001).
30. Shen, S. et al. MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data. Nucleic Acids Res. 40, e61-e61 (2012).
31. Boussadia, O., Jacquemin-Sablon, H. & Dautry, F. Exon skipping in the expression of the gene immediately upstream of N-ras (unr/NRU). Biochim. Biophys. Acta 1172, 64-72 (1993).
32. Bian, Y. et al. Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome. Hum. Mol. Genet. 18, 1229-1237 (2009).
33. Incitti, T. et al. Exon skipping and Duchenne muscular dystrophy therapy: selection of the most active U1 snRNA antisense able to induce dystrophin exon 51 skipping. Mol. Ther. 18, 1675-1682 (2010).
34. Savkur, R. S., Philips, A. V. & Cooper, T. A. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29, 40-47 (2001).
35. van den Bergen, J. C. et al. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J. Neurol. Neurosurg. Psychiatry 85, 747-753 (2014).
36. van Putten, M. et al. The effects of low levels of dystrophin on mouse muscle function and pathology. PLoS ONE 7, e31937 (2012).
37. Godfrey, C. et al. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse. Hum. Mol. Genet. 24, 4225-4237 (2015).
38. Nigro, G., Comi, L. I., Politano, L. & Bain, R. J. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 26, 271-277 (1990).
39. Martone, J., De Angelis, F. G. & Bozzoni, I. U1 snRNA as an effective vector for stable expression of antisense molecules and for the inhibition of the splicing reaction. Methods Mol. Biol. 867, 239-257 (2012).
40. Choi, J. et al. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc. Natl Acad. Sci. USA 87, 7988-7992 (1990).